VRCI - Ticker AI Digest

Verici Dx Plc 📰 2
TradingFloor AI GO VIP Login

Digested News

Today's Catalysts (VRCI) 2
VRCI 06:02
Verici Dx Plc
FY25 Trading Update
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Verici Dx PLC, a developer of advanced clinical diagnostics for organ transplant, released its FY25 trading update on February 5, 2026, highlighting strong growth and commercial progress. Key financial and operational achievements include
1. **Financial Highlights**
Total unaudited revenues of $3.8 million (up from $3.3 million in 2024), driven by $3.0 million from Tutiviaâ„¢ test revenues and $0.8 million from license income.
Cash position of $3.3 million at year-end, slightly ahead of expectations, with $1.6 million in accounts receivable, supporting runway into H2 2026.
2. **Operational Highlights**
Significant commercial progress with first revenues from Tutiviaâ„¢, a post-kidney transplant test for early rejection detection.
Secured Medicare coverage for Tutiviaâ„¢, covering 68% of US transplant tests, enhancing patient access.
Milestone payment of $0.8 million from Thermo Fisher Scientific for PTRA (Clarava) licensing.
Increased test adoption1,173 Tutiviaâ„¢ tests ordered in FY25 (vs. 334 in FY24), with 34 centers using the test (18% of US kidney transplants).
Strategic partnerships with Prime Health Services and Blue Cross Blue Shield of Illinois to expand access and reimbursement.
3. **Future Outlook**
CEO Sara Barrington expressed confidence in continued growth, despite Tutiviaâ„¢ revenues slightly missing market expectations, citing strong testing volume acceleration and robust clinical and regulatory foundations.
Full-year audited results expected by May 2026.
Verici Dx remains focused on transforming transplant patient care through precision diagnostics, leveraging multiomic analysis and AI to optimize therapy and improve outcomes.
VRCI 06:01
Verici Dx Plc
Agreement with BCBS of Illinois for Tutiviaâ„¢
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Verici Dx PLC, a precision diagnostics company focused on organ transplant care, has entered into a significant agreement with Blue Cross and Blue Shield (BCBS) of Illinois for its post-kidney transplant <mark style="background-color:yellow">test</mark>, Tutivia™. This agreement ensures that Tutivia is recognized as an in-network benefit, simplifying the claims process and providing patients with access to testing at in-network rates. Verici Dx has also joined BCBS’s Preferred Provider Organization network, granting the company access to open contract processes with other BCBS entities, including BCBS Texas. The agreement covers all BCBS lines of business in Illinois, including commercial, managed Medicaid, and Medicare Advantage, and provides access to the BCBS Association, which includes 33 member entities. This milestone expands Verici Dx’s commercial reach and patient network, with CEO Sara Barrington emphasizing its importance for the company’s growth. Verici Dx, headquartered in the UK and U.S., leverages multiomic analysis and AI to develop advanced diagnostics for transplant patients, with Tutivia™ as its lead product for early detection of acute kidney transplant rejection.
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 1
VRCI 06:01
Verici Dx Plc
Agreement with BCBS of Illinois for Tutiviaâ„¢
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Verici Dx PLC, a precision diagnostics company focused on organ transplant care, has entered into a significant agreement with Blue Cross and Blue Shield (BCBS) of Illinois for its post-kidney transplant <mark style="background-color:yellow">test</mark>, Tutivia™. This agreement ensures that Tutivia is recognized as an in-network benefit, simplifying the claims process and providing patients with access to testing at in-network rates. Verici Dx has also joined BCBS’s Preferred Provider Organization network, granting the company access to open contract processes with other BCBS entities, including BCBS Texas. The agreement covers all BCBS lines of business in Illinois, including commercial, managed Medicaid, and Medicare Advantage, and provides access to the BCBS Association, which includes 33 member entities. This milestone expands Verici Dx’s commercial reach and patient network, with CEO Sara Barrington emphasizing its importance for the company’s growth. Verici Dx, headquartered in the UK and U.S., leverages multiomic analysis and AI to develop advanced diagnostics for transplant patients, with Tutivia™ as its lead product for early detection of acute kidney transplant rejection.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 0
No items for this category on selected date.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 0
No items for this category on selected date.
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 1
VRCI 06:02
Verici Dx Plc
FY25 Trading Update
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Verici Dx PLC, a developer of advanced clinical diagnostics for organ transplant, released its FY25 trading update on February 5, 2026, highlighting strong growth and commercial progress. Key financial and operational achievements include
1. **Financial Highlights**
Total unaudited revenues of $3.8 million (up from $3.3 million in 2024), driven by $3.0 million from Tutiviaâ„¢ test revenues and $0.8 million from license income.
Cash position of $3.3 million at year-end, slightly ahead of expectations, with $1.6 million in accounts receivable, supporting runway into H2 2026.
2. **Operational Highlights**
Significant commercial progress with first revenues from Tutiviaâ„¢, a post-kidney transplant test for early rejection detection.
Secured Medicare coverage for Tutiviaâ„¢, covering 68% of US transplant tests, enhancing patient access.
Milestone payment of $0.8 million from Thermo Fisher Scientific for PTRA (Clarava) licensing.
Increased test adoption1,173 Tutiviaâ„¢ tests ordered in FY25 (vs. 334 in FY24), with 34 centers using the test (18% of US kidney transplants).
Strategic partnerships with Prime Health Services and Blue Cross Blue Shield of Illinois to expand access and reimbursement.
3. **Future Outlook**
CEO Sara Barrington expressed confidence in continued growth, despite Tutiviaâ„¢ revenues slightly missing market expectations, citing strong testing volume acceleration and robust clinical and regulatory foundations.
Full-year audited results expected by May 2026.
Verici Dx remains focused on transforming transplant patient care through precision diagnostics, leveraging multiomic analysis and AI to optimize therapy and improve outcomes.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 2
VRCI 06:02
Verici Dx Plc
FY25 Trading Update
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Verici Dx PLC, a developer of advanced clinical diagnostics for organ transplant, released its FY25 trading update on February 5, 2026, highlighting strong growth and commercial progress. Key financial and operational achievements include
1. **Financial Highlights**
Total unaudited revenues of $3.8 million (up from $3.3 million in 2024), driven by $3.0 million from Tutiviaâ„¢ test revenues and $0.8 million from license income.
Cash position of $3.3 million at year-end, slightly ahead of expectations, with $1.6 million in accounts receivable, supporting runway into H2 2026.
2. **Operational Highlights**
Significant commercial progress with first revenues from Tutiviaâ„¢, a post-kidney transplant test for early rejection detection.
Secured Medicare coverage for Tutiviaâ„¢, covering 68% of US transplant tests, enhancing patient access.
Milestone payment of $0.8 million from Thermo Fisher Scientific for PTRA (Clarava) licensing.
Increased test adoption1,173 Tutiviaâ„¢ tests ordered in FY25 (vs. 334 in FY24), with 34 centers using the test (18% of US kidney transplants).
Strategic partnerships with Prime Health Services and Blue Cross Blue Shield of Illinois to expand access and reimbursement.
3. **Future Outlook**
CEO Sara Barrington expressed confidence in continued growth, despite Tutiviaâ„¢ revenues slightly missing market expectations, citing strong testing volume acceleration and robust clinical and regulatory foundations.
Full-year audited results expected by May 2026.
Verici Dx remains focused on transforming transplant patient care through precision diagnostics, leveraging multiomic analysis and AI to optimize therapy and improve outcomes.
VRCI 06:01
Verici Dx Plc
Agreement with BCBS of Illinois for Tutiviaâ„¢
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Verici Dx PLC, a precision diagnostics company focused on organ transplant care, has entered into a significant agreement with Blue Cross and Blue Shield (BCBS) of Illinois for its post-kidney transplant <mark style="background-color:yellow">test</mark>, Tutivia™. This agreement ensures that Tutivia is recognized as an in-network benefit, simplifying the claims process and providing patients with access to testing at in-network rates. Verici Dx has also joined BCBS’s Preferred Provider Organization network, granting the company access to open contract processes with other BCBS entities, including BCBS Texas. The agreement covers all BCBS lines of business in Illinois, including commercial, managed Medicaid, and Medicare Advantage, and provides access to the BCBS Association, which includes 33 member entities. This milestone expands Verici Dx’s commercial reach and patient network, with CEO Sara Barrington emphasizing its importance for the company’s growth. Verici Dx, headquartered in the UK and U.S., leverages multiomic analysis and AI to develop advanced diagnostics for transplant patients, with Tutivia™ as its lead product for early detection of acute kidney transplant rejection.

AI Crunch

Single-Ticker AI Crunch
VRCI signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for Verici Dx Plc. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full VRCI AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for VRCI on 2026-02-05.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
6810274
Enterprise Value
14273793
Public Float
11.34
Broker Target
2.9
Shares Out
1513394127
Long Interest
93
Short Interest
7
Exchange
LSE
Currency Code
GBX
ISIN
GB00BM8HZD43
Market
LSE - AIM
Sector
Health Care
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2009-01-01
Earnings Date
-
Net Debt
-3690000.0
Cash
4061000.0
EPS
-0.02
Net Income
-5874000.0
Revenue
3339000.0
Enterprise Value
14273793
Trailing PE
-
Forward PE
-
Price Sales TTM
3.56
Price Book MRQ
3.8894
EV Revenue
4.9495
EV EBITDA
-1.574

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
34.1577
Institutions As Of
2026-04-10
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
0
Sale Director Dealing
0
Purchase TR1
5
Sale TR1
5
Broker Coverage Rows
0
Institution Holders Tracked
6
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

Today's Catalysts

2 live catalysts just hit VRCI.

The headlines landing in Digested News are now framed here as today's catalyst tape. Scroll the tab rail to Digested News or jump there instantly below.
Live Tape Data 2026-02-05 AI Charts Landing View
Scroll the tab rail to Digested News any time, or use the jump button to land straight on today's tape.
2 Today
Catalyst Pulse
Verici Dx Plc has fresh news flow feeding the chart narrative.
AI Charts Studio
VRCI Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2026-02-05 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
RSI Gauge
Price Change
AI Forecast